Request Information
Request Information
Jan 21 2021
REDWOOD CITY, CALIF. – January 21, 2021 – Ethicon’s* Auris Health, Inc., part of Johnson & Johnson Medical Devices**, today announced results from the world’s first prospective, multicenter study of robotic bronchoscopy. The study, called BENEFIT, evaluated the safety and feasibility of the MONARCH® Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures. Results of the study were published in CHEST, the official publication of the American College of Chest Physicians.
Continue ReadingJul 30 2020
New Brunswick, N.J., July 30, 2020 – Ethicon, a Johnson & Johnson Medical Devices Company*, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development.
Continue ReadingOct 23 2019
NEW ORLEANS – October 23, 2019 – Auris Health, Inc. (“Auris Health”), part of Johnson & Johnson Medical Devices Companies,* today announced results from a study demonstrating the safety and feasibility of the Monarch Platform, a first-of-its-kind robotic technology indicated for use in diagnostic and therapeutic bronchoscopic procedures. Data from the BENEFIT study was presented in a late-breaking session at the CHEST 2019 Conference in New Orleans by Alexander C. Chen, M.D., of St. Louis, Mo.
Continue ReadingAug 26 2019
REDWOOD CITY – August 22, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, today announced that physicians have performed over 1,000 bronchoscopic procedures using the Monarch™ Platform. Auris gained FDA clearance for diagnostic and therapeutic bronchoscopic procedures on the Monarch Platform in the Spring of 2018.
Continue ReadingMay 21 2019
Redwood City, Calif. and Dallas – May 21, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies,* today announced that interim results from an independent pilot feasibility study designed to evaluate the company’s Monarch Platform were presented at the American Thoracic Society (ATS) 2019 Conference in Dallas. The Monarch Platform is a first-of-its-kind robotic technology cleared by the U.S. Food and Drug Administration (FDA) for diagnostic and therapeutic bronchoscopic procedures.
Continue ReadingMay 20 2019
DALLAS – May 20, 2019 – Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies,* today announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platform, a first-of-its-kind robotic technology cleared by the U.S. Food and Drug Administration (FDA) for diagnostic and therapeutic bronchoscopic procedures. Preliminary data from the study was presented by Alexander C. Chen, M.D., of St. Louis, Mo., at the American Thoracic Society (ATS) 2019 Conference in Dallas.
Continue ReadingApr 19 2019
REDWOOD CITY, Calif. – April 19, 2019 – Auris Health, Inc., a part of Johnson & Johnson Medical Devices Companies, today announced that the Monarch Platform has been recognized with a Gold 2019 Edison Award and a Red Dot: Best of the Best Award. Both award organizations recognize the best products and innovators from around the world. Auris™ creators of the first-of-its-kind robotic endoscopy technology, is being honored for its innovative approach to revolutionizing the diagnosis of lung disease.
Continue ReadingApr 01 2019
NEW BRUNSWICK, NJ – April 1, 2019 –Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. With Auris Health’s robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson & Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties.
Continue ReadingFeb 13 2019
NEW BRUNSWICK, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. This acquisition will accelerate Johnson & Johnson’s entry into robotics with potential for growth and expansion into other interventional applications.
Continue ReadingNov 28 2018
REDWOOD CITY, Calif. – November 28, 2018 – Auris Health, Inc. today announced the close of a $220 million equity financing led by Partner Fund Management. New investors Wellington Management, D1 Capital Partners and Senator Investment Group and existing investors including Mithril Capital, Lux Capital and Viking Global Investors also participated in the round. The company has now raised more than $700 million to date. Funding will be used to advance the commercialization of the company’s Monarch™ Platform and the development of next-generation robotic interventional technology.
Continue Reading